Aprepitant

Drug Overview

Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. It was the first drug in its class approved by the FDA and represents a significant advancement in antiemetic therapy, particularly for the prevention of delayed nausea and vomiting associated with chemotherapy.

• Generic Name: Aprepitant
• US Brand Names: Emend® (Capsules/Suspension), Cinvanti® (Injectable Emulsion)
• Drug Class: Substance P/Neurokinin 1 (NK1) Receptor Antagonist
• Route of Administration: Oral (Capsules, Suspension) or Intravenous (IV) Infusion
• FDA Approval Status: Approved for the prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).

What Is It and How Does It Work? (Mechanism of Action)

Aprepitant functions by blocking specific signals in the brain’s vomiting center, distinct from how older antiemetics work.

• Molecular Target: The drug selectively binds to Neurokinin 1 (NK1) receptors located in the brainstem (nucleus tractus solitarius and area postrema).
• Blockade of Substance P: Chemotherapy triggers the release of Substance P, a neuropeptide that binds to NK1 receptors to induce vomiting. Aprepitant acts as a competitive antagonist, preventing Substance P from binding to these receptors.
• Delayed Phase Control: Unlike 5-HT3 antagonists (e.g., ondansetron), which primarily target the acute phase (first 24 hours), aprepitant is particularly effective at blocking the delayed phase of emesis (24–120 hours post-chemotherapy), which is primarily mediated by Substance P.
• Augmentation: It has been shown to augment the antiemetic activity of 5-HT3 receptor antagonists and corticosteroids, creating a synergistic effect.

FDA-Approved Clinical Indications

Aprepitant is FDA-approved for prevention strategies rather than treating established nausea.

Oncological Uses:

• Highly Emetogenic Chemotherapy (HEC): Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (e.g., high-dose cisplatin).
• Moderately Emetogenic Chemotherapy (MEC): Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Non-Oncological Uses:

• Postoperative Nausea and Vomiting (PONV): Prevention of postoperative nausea and vomiting in adult patients.

Dosage and Administration Protocols

Dosage regimens vary significantly between chemotherapy prevention and surgical prevention. The standard oral regimen for chemotherapy is a 3-day protocol.

Standard Oncology Dosage (CINV):

• Regimen: 3-Day Protocol.
• Combination: Must be administered with a 5-HT3 antagonist (Day 1) and a corticosteroid (Day 1-4).
• Timing: The first dose is given 1 hour before chemotherapy.

Surgical Dosage (PONV):

• Single Dose: 40 mg administered orally within 3 hours before the induction of anesthesia.

Organ Function Adjustments:

• Renal Impairment: No dosage adjustment is necessary for patients with severe renal impairment or End Stage Renal Disease (ESRD) undergoing hemodialysis.
• Hepatic Impairment: No dosage adjustment for mild to moderate impairment (Child-Pugh score 5-9). Data is lacking for severe impairment.

Clinical Efficacy and Research Results

Clinical data from 2020-2025 emphasize the efficacy of aprepitant-containing “triple therapy” regimens.

• Complete Response Rates: In studies involving highly emetogenic chemotherapy (HEC), the addition of aprepitant to standard therapy increased the percentage of patients achieving “Complete Response” (no vomiting and no rescue medication) in the delayed phase to approximately 75% compared to 40-50% in control groups.
• Platinum-Based Chemotherapy: Recent meta-analyses (2023) confirmed that aprepitant significantly reduces the risk of vomiting in lung cancer patients receiving platinum-based doublets, with effective control rates of acute vomiting reaching 83.3%.
• Stem Cell Transplant Conditioning: In patients undergoing high-dose melphalan conditioning for stem cell transplants, aprepitant significantly improved Complete Protection rates (no emesis) compared to controls (85% vs 33%), validating its utility in high-dose preparative regimens.

Safety Profile and Side Effects

Important Warnings:

While there is no Black Box Warning, Drug Interactions are a critical safety concern. Aprepitant is a substrate, inhibitor, and inducer of CYP3A4.

Common Side Effects (>10%)

• Gastrointestinal: Constipation, diarrhea, and dyspepsia.
• General: Fatigue and weakness (asthenia).
• Respiratory: Hiccups are a distinct and frequent side effect of NK1 antagonists.
• Hepatic: Mild elevations in ALT/AST liver enzymes.

Serious Adverse Events

• Hypersensitivity: Anaphylaxis and severe skin reactions (Stevens-Johnson Syndrome) have been reported, particularly with the fosaprepitant prodrug but possibly with aprepitant.
• Drug Interaction Toxicity: Because it inhibits CYP3A4, it can dangerously increase levels of chemotherapies metabolized by this enzyme (e.g., ifosfamide, vincristine), potentially leading to neurotoxicity.

Management Strategies:

• Dexamethasone Adjustment: The dose of oral dexamethasone must be reduced by approximately 50% when co-administered with aprepitant, as aprepitant increases dexamethasone blood levels.
• Hiccups: Usually self-limiting; intractable cases may require medical intervention (e.g., baclofen).

Connection to Stem Cell and Regenerative Medicine

Aprepitant has a dual role in the context of stem cell biology: as a supportive care agent and a potential modulator of the bone marrow microenvironment.

• Supportive Care in HSCT: High-dose conditioning regimens (like Melphalan) used before Hematopoietic Stem Cell Transplantation (HSCT) are highly emetogenic. Aprepitant is frequently used off-label or in trials to prevent the severe delayed vomiting associated with these transplants, significantly improving patient quality of life during the critical engraftment period.
• Modulation of Substance P in Bone Marrow: Research indicates that Substance P regulates the proliferation of bone marrow stem cells and induces cytokines (IL-1, SCF) in the marrow stroma. By antagonizing NK1 receptors, aprepitant may modulate this inflammatory microenvironment, which is currently being explored for its potential to reduce the progression of bone-marrow-resident cancers like multiple myeloma or leukemia.
• Antitumor Potential: Preclinical studies suggest that NK1 receptor antagonists like aprepitant may exert direct antiproliferative and antiangiogenic effects on tumors that overexpress NK1 receptors (such as pancreatic cancer and neuroblastoma), independent of their antiemetic properties.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• Medication Review: A comprehensive review of all current medications is mandatory to identify CYP3A4 interactions.
• INR Check: For patients on Warfarin, baseline INR is required.

Precautions During Treatment:

• Warfarin Monitoring: Aprepitant induces the metabolism of Warfarin (CYP2C9), leading to a decrease in INR. INR should be closely monitored for 2 weeks after each 3-day cycle.
• Contraception Failure: Aprepitant can reduce the efficacy of hormonal contraceptives (birth control pills). Patients must use an alternative, non-hormonal backup method of birth control during treatment and for 1 month after the last dose.

Do’s and Don’ts:

• DO: Take the first capsule 1 hour before chemotherapy starts.
• DO: Swallow the capsule whole; do not open or crush it.
• DON’T: Change the dose of your steroid (dexamethasone) without instruction; the doctor has likely already lowered it to account for the drug interaction.
• DON’T: Drink grapefruit juice in large quantities while on this medication.

Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.